ERBB2 and apocrine adenocarcinoma: The therapeutic strategy consisted of neoadjuvant chemotherapy combined with dual HER2-targeted therapy, followed by mastectomy with axillary lymph node dissection, adjuvant radiotherapy, and maintenance therapy with trastuzumab and pertuzumab. Given the rarity of HER2-positive apocrine carcinoma and the scarcity of data on its optimal management, this report aims to contribute to the existing literature by highlighting the efficacy of a personalized, multimodal therapeutic approach in an oligometastatic context.